Abbott to Acquire Exact Sciences, a Leader in Large and Fast-Growing Cancer Screening and Precision Oncology Diagnostics Segments

Abbott to Acquire Exact Sciences in a $21 Billion Deal

On November 20, 2025, Abbott announced it would acquire Exact Sciences, a leader in cancer screening and precision oncology diagnostics. The deal values Exact Sciences at approximately $21 billion, with shareholders receiving $105 per share in cash.

Details of the Acquisition

Abbott's purchase of Exact Sciences, based in Madison, Wisconsin, places the company at the forefront of the rapidly expanding cancer diagnostics market, estimated at $60 billion in the U.S. [web:1][web:2].

Strategic Importance

The acquisition adds a new growth segment to Abbott’s portfolio, focusing on early detection and personalized treatment of cancer [web:4].
Exact Sciences' product lineup includes advanced tests such as Cologuard®, Oncotype DX®, Oncodetect™, and Cancerguard™, which support early diagnostics and treatment decisions [web:2][web:4].
Once finalized, the deal is expected to be immediately accretive to Abbott's revenue and profit margins, with the transaction closing anticipated in the second quarter of 2026 [web:7].

Market Impact and Future Outlook

The deal will enable Abbott to expand access to innovative cancer diagnostics, improve early detection, and help more patients manage and treat cancer at its earliest, most treatable stages.

Summary

Abbott's acquisition of Exact Sciences signifies a major step into the growing cancer diagnostics industry, aiming to enhance early detection tools and personalized cancer care, serving millions worldwide.

Urban Milwaukee — 2025-11-20

Abbott to Acquire Exact Sciences in a $21 Billion Deal

Details of the Acquisition

Strategic Importance

Market Impact and Future Outlook

Summary

More News